Compliance Monitor (CM) Overview and Application Process

AI Summary

Starting in April 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) initiated a pilot program for companies failing to meet Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) standards. This guidance addresses firms referred to the Inspection Action Group (IAG) after inspections reveal significant non-compliance that triggers formal escalation. While the document describes a general regulatory framework rather than a specific enforcement action against a single company, it outlines the path for entities struggling with manufacturing and distribution quality standards. Under this pilot, eligible companies are offered the opportunity to work with independent Compliance Monitors (CM) to oversee a structured Compliance Protocol (CP). This protocol serves as a roadmap for required actions, focusing on remediating corrective issues and ensuring a safe supply of medicines. Participation allows firms to benefit from intensive, independent oversight while the MHRA focuses its resources on broader inspection programs. Companies may choose to decline this route and remain within the standard IAG enforcement process. The ultimate goal of the initiative is to reduce the risk of drug shortages and enhance patient safety by accelerating the remediation of systemic quality failures through expert third-party monitoring.